Argent BioPharma (ASX:RGT) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RGT 주식 개요

신약 개발 임상 단계의 바이오 제약 회사인 Argent BioPharma Limited는 면역학 및 신경학을 대상으로 하는 의약품을 전 세계에 공급하는 회사입니다.

RGT 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	3/6
배당금	0/6

보상

위험 분석

수익이 1백만 달러 미만인 경우 ( A$1M )

지난 5년간 매년 수익이 12% 씩 감소했습니다.

지난 1년 동안 주주가 크게 희석되었습니다.

의미 있는 시가총액이 없습니다. ( A$14M )

Argent BioPharma Limited 경쟁사

Ecofibre

ASX:EOF

AU$11.0m

Firebrick Pharma

ASX:FRE

AU$10.9m

Emyria

ASX:EMD

AU$16.8m

Island Pharmaceuticals

ASX:ILA

AU$9.0m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Argent BioPharma
과거 주가
현재 주가	AU$0.30
52주 최고치	AU$6.00
52주 최저치	AU$0.25
베타	1.05
11개월 변경	-16.67%
3개월 변경 사항	-26.83%
1년 변경 사항	-94.00%
33년 변화	-99.25%
5년 변화	-99.41%
IPO 이후 변화	-99.79%

최근 뉴스 및 업데이트

Recent updates

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

Feb 21

What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

Dec 30

주주 수익률

	RGT	AU Pharmaceuticals	AU 마켓
7D	0%	6.5%	-0.3%
1Y	-94.0%	71.6%	8.3%

수익률 대 산업: RGT 지난 1년 동안 64.4 %를 반환한 Australian Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: RGT 지난 1년 동안 6.7 %를 반환한 Australian 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is RGT's price volatile compared to industry and market?
RGT volatility
RGT Average Weekly Movement	10.8%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	3.2%

안정적인 주가: RGT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: RGT 의 주간 변동성은 지난 1년 동안 38% 에서 9% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
2014	n/a	Roby Zomer	argentbiopharma.com

신약 개발 임상 단계의 바이오 제약 회사인 Argent BioPharma Limited는 면역학 및 신경학을 대상으로 하는 의약품을 전 세계에 공급하고 있습니다. 주요 제품 후보로는 SLE 루푸스, 항염증제, SARS COVID-19 치료를 위한 임상 2상 시험 중인 시메트라와 난치성 간질 및 뇌성마비 치료를 위한 임상 1상 시험 중인 칸에필, 치매 및 알츠하이머 증상 완화를 위한 임상 1상 시험 중인 코그니캔 등이 있습니다. 또한 뇌암 치료제인 이리니칸도 공급하고 있습니다.

Argent BioPharma Limited 기본 사항 요약

Argent BioPharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
RGT 기본 통계
시가총액	AU$13.58m
수익(TTM)	-AU$17.02m
수익(TTM)	AU$1.32m

10.3x

P/S 비율

-0.8x

P/E 비율

RGT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
RGT 손익 계산서(TTM)
수익	AU$1.32m
수익 비용	AU$1.20m
총 이익	AU$125.39k
기타 비용	AU$17.14m
수익	-AU$17.02m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.38
총 마진	9.47%
순이익 마진	-1,284.89%
부채/자본 비율	1,366.5%

RGT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

RGT 주식 개요

보상

위험 분석

Argent BioPharma Limited 경쟁사

ASX:EOF

AU$11.0m

ASX:FRE

AU$10.9m

ASX:EMD

AU$16.8m

ASX:ILA

AU$9.0m

가격 내역 및 성능

최근 뉴스 및 업데이트

New major risk - Market cap size

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Recent updates

New major risk - Market cap size

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Price target decreased to AU$0.04

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

Price target decreased to AU$0.07

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding